- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.06. | CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last? | 1 | Zacks | ||
| 09.06. | CVRx CFO Oasheim To Step Down | 1 | RTTNews | ||
| CVRX Aktie jetzt für 0€ handeln | |||||
| 09.06. | CVRx CFO Jared Oasheim to step down | 1 | Seeking Alpha | ||
| 09.06. | CVRx, Inc.: CVRx Announces Chief Financial Officer Transition | 278 | GlobeNewswire (Europe) | MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation... ► Artikel lesen | |
| 03.06. | CVRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.05. | CVRx earns Humana Medicare Advantage win for Barostim | 1 | MassDevice | ||
| 14.05. | CVRx rebounds as Humana issues Medicare policy for Barostim | 2 | Seeking Alpha | ||
| 14.05. | CVRx, Inc.: CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy | 2 | GlobeNewswire (USA) | ||
| 12.05. | CVRx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.05. | CVRx signals $63M-$67M 2026 revenue outlook as Category I CPT transition reshapes prior authorization dynamics | 1 | Seeking Alpha | ||
| 11.05. | CVRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.05. | CVRx enrolls first patient in 2,500-patient heart failure trial | 2 | Investing.com | ||
| 04.05. | CVRx enrolls first patient in study of Barostim therapy for heart failure | - | MassDevice | ||
| 04.05. | CVRx, Inc.: CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population | 136 | GlobeNewswire (Europe) | MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for... ► Artikel lesen | |
| 01.05. | CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 20.04. | CVRx nominates Michael Dale to board of directors | 4 | Investing.com | ||
| 20.04. | CVRx nominiert Michael Dale für den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 20.04. | CVRx, Inc.: CVRx Announces Nomination of Michael Dale for Election to the Board of Directors | 2 | GlobeNewswire (USA) | ||
| 13.04. | William Blair reiterates CVRx stock rating on strong Q1 results | 2 | Investing.com | ||
| 13.04. | CVRx sees Q1 revenue in the range of $14.7M to $14.8M | 2 | Seeking Alpha |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO-DIAGNOSTICS | 1,500 | +4,17 % | EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test | ||
| CYTOSORBENTS | 0,324 | +1,89 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,750 | +3,88 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| FULGENT GENETICS | 15,100 | +5,59 % | Fulgent expects $330M-$340M 2026 revenue as billing transition lowers collection rates | ||
| EMBECTA | 3,159 | -0,06 % | Picard Medical, Inc.: Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026 | ||
| CHECK-CAP | 0,915 | -1,61 % | Humanoid Global meldet Fortschritte von MBody AI bei der kommerziellen Expansion und dem geplanten Unternehmenszusammenschluss mit Check-Cap | Vancouver, BC / 14. Juli 2026 / IRW-Press / Humanoid Global
Holdings Corp. ("Humanoid Global" oder das "Unternehmen")
(CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), ein börsennotierter
Investment-Emittent... ► Artikel lesen | |
| ELECTROCORE | 5,150 | -3,74 % | electroCore, Inc.: electroCore Announces Full Year 2025 Financial Results and Organizational Changes | Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness... ► Artikel lesen | |
| CATHETER PRECISION | 0,255 | +0,47 % | Catheter Precision, Inc. - 8-K, Current Report | ||
| CLEARPOINT NEURO | 15,230 | +1,94 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy Designation for Sasineprocel | RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire... ► Artikel lesen | |
| ENVUE MEDICAL | 0,323 | +2,38 % | ENvue Medical, Inc.: ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform | Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing... ► Artikel lesen | |
| ENDRA LIFE SCIENCES | 4,700 | -1,47 % | ASP Isotopes Inc.: ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing | Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen's Virginia Gas Project Listing expected to provide investors with direct exposure to one of... ► Artikel lesen | |
| FIREFLY NEUROSCIENCE | 1,180 | +10,28 % | Firefly Neuroscience, Inc.: Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides | ||
| FEMASYS | 2,920 | +2,46 % | Femasys Inc.: Femasys Regains Compliance with Nasdaq Listing Requirements | ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective... ► Artikel lesen | |
| CUPRINA HOLDINGS | 2,750 | -5,82 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| EXAGEN | 3,880 | -3,00 % | Exagen Inc. Reports First Quarter 2026 Results | CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026... ► Artikel lesen |
Das Unternehmen CVRX INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +6,47 % bei einem Aktienkurs von 5,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CVRX INC finden Sie auf Wallstreet Online.